Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist
Phase 3RecruitingDevelopment Stage
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Dec 11, 2023 → Feb 12, 2029
About Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist
Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist is a phase 3 stage product being developed by Roche for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06065748. Target conditions include Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer.
What happened to similar drugs?
1 of 2 similar drugs in Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06065748 | Phase 3 | Recruiting |
Competing Products
20 competing products in Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer